UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN)

Historical Holders from Q2 2017 to Q3 2025

Symbol
URGN on Nasdaq
Type / Class
Equity / Ordinary Shares, par value NIS 0.01 per share
Shares outstanding
46.2M
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
43.9M
Holdings value
$877M
% of all portfolios
0.002%
Grand Portfolio weight change
+0%
Number of holders
158
Number of buys
81
Number of sells
-67
Average Value change %
0%
Average buys %
+0.001%
Average sells %
-0.002%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Paradigm Biocapital Advisors LP 9% +80% $84.1M $37.6M 4.22M +80.8% Paradigm BioCapital Advisors LP 30 Sep 2025
TORONTO DOMINION BANK 6.9% $63.7M 3.19M The Toronto-Dominion Bank 30 Sep 2025
MORGAN STANLEY 5.4% +180% $35.4M $24.7M 2.49M +231% Morgan Stanley 30 Jun 2025
MENORA MIVTACHIM HOLDINGS LTD. 4.99% $24.8M 2.3M Menora Mivtachim Holdings Ltd 11 Mar 2025
BlackRock, Inc. 5% $31.3M 2.28M BlackRock, Inc. 30 Jun 2025
Soleus Capital Master Fund, L.P. 4.7% -6% $31.1M -$1.99M 2.19M -6.02% Soleus Capital Master Fund, L.P. 30 Jun 2025
Adage Capital Management, L.P. 2.77% -59.6% $13.7M -$17.8M 1.28M -56.4% Adage Capital Management, L.P. 31 Mar 2025
Monograph Capital Holdings Advisors, LLC 1.8% $8.5M 839K Monograph Capital Partners I, L.P. 05 Jun 2025

Institutional Holders of UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 43.9M $877M +$94.3M $19.95 158
2025 Q2 39.8M $545M +$3.48M $13.70 149
2025 Q1 41.6M $461M +$59.8M $11.06 139
2024 Q4 36.3M $387M -$9.61M $10.65 139
2024 Q3 35.1M $446M -$58.5M $12.70 127
2024 Q2 38.2M $641M +$207M $16.78 114
2024 Q1 27.2M $407M +$84.9M $15.00 111
2023 Q4 21.4M $321M +$51.9M $15.00 103
2023 Q3 17.7M $248M +$65.7M $14.01 100
2023 Q2 13.2M $137M +$7.18M $10.35 84
2023 Q1 12.4M $115M -$4.45M $9.24 64
2022 Q4 13M $115M -$2.38M $8.87 63
2022 Q3 13.3M $111M -$982K $8.32 56
2022 Q2 13.4M $109M -$6.04M $8.19 60
2022 Q1 14.2M $124M +$1.87M $8.71 82
2021 Q4 14.7M $139M +$2.18M $9.51 71
2021 Q3 14.1M $237M +$1.24M $16.82 88
2021 Q2 14M $214M -$5.53M $15.27 78
2021 Q1 14.3M $278M -$4.2M $19.48 88
2020 Q4 14.5M $262M -$10.5M $18.02 81
2020 Q3 15M $289M +$6.24M $19.29 78
2020 Q2 14.7M $382M +$28.3M $26.12 83
2020 Q1 14M $249M -$10M $17.84 78
2019 Q4 14.2M $473M +$4.84M $33.37 85
2019 Q3 14.6M $347M -$26.2M $23.83 83
2019 Q2 14.7M $527M +$43.9M $35.94 84
2019 Q1 13.5M $497M +$143M $36.94 73
2018 Q4 9.59M $413M +$18.6M $43.06 63
2018 Q3 9.92M $469M +$14.7M $47.23 70
2018 Q2 9.6M $482M +$24.1M $49.76 60
2018 Q1 9.14M $454M +$119M $49.69 43
2017 Q4 5.74M $214M +$83.1M $37.21 40
2017 Q3 3.12M $98.4M +$1.69M $31.52 29
2017 Q2 4.72M $85.2M +$85.2M $18.06 21